Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted
Recommend 11 Positive 20 Negative 9 |
||||
|
||||
|
HUTCHMED (00013.HK) and INNOVENT BIO (01801.HK) jointly announced that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma (RCC) who have failed prior treatment with one tyrosine kinase inhibitor has been accepted for review by the China National Medical Products Administration. HUTCHMED opened 2.53% higher this morning and once climbed to a peak of HKD25.1. It last traded at HKD24.85, up 4.85%, on a volume of 2.623 million shares and a turnover of HKD64.9228 million. Hyped up yesterday, INNOVENT BIO opened flat this morning and once sank to a bottom of HKD71.8. It was last at HKD72.1, down 2.9%, on a volume of 4.4799 million shares and a turnover of HKD326 million. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
